BioCentury
ARTICLE | Financial News

EndoCeutics pulls IPO

June 29, 2007 1:17 AM UTC

EndoCeutics (Quebec City, Quebec) withdrew its IPO, citing market conditions and undisclosed changes made to its clinical trials schedule. In May, the company said it would start a Phase III trial next half of lead candidate acolbifene, a selective estrogen receptor modulator (SERM), to treat advanced breast cancer in women who have failed hormone therapy. The company also said in May that it planned to begin a Phase III trial this year of its dehydroepiandrosterone (DHEA) to treat vaginal atrophy. The company was unavailable for comment. ...